Venture fund & syndicate investing in the future of mental and brain health: psychedelic medicine, neurotechnology, precision psychiatry, alternative modalities and digital therapeutics.
External link for PsyMed Ventures
San Francisco, CA 94117, US
PsyMed Ventures reposted this
We invested in Jimini Health! The future of therapy is AI-augmented. Jimini is building clinically integrated LLMs for mental health that work alongside human therapists. So much happens in between sessions. Imagine having a 24/7 virtual care assistant to help with support, exercises, and "aha!" moments. https://lnkd.in/ejFzH5Dj
PsyMed Ventures GP Greg Kubin will join Jimini Health Chief Clinical Officer Dr. Bill Hudenko and Icahn School of Medicine at Mount Sinai Assistant Professor Dr. Allison C. Waters, PhD to talk about AI augmented therapy in New York TOMORROW, November 21st at 5pm. Sign up here: https://lnkd.in/gDK4CyUF
AI can analyze complex interactions, such as mood patterns, gene expression, and the timing of genetic therapy, and create transformative solutions that were once unaccessible to humans. Listen to Dana Watt, PhD of Breakout Ventures on the latest Business Trip Episode. Full episode here: https://lnkd.in/gWdJT3qR
NEW Business Trip Episode “Genetic Medicine for Brain Health” with Dana Watt, PhD of Breakout Ventures. In this episode we discuss: - How genetic therapies work: addressing underlying causes, not just symptoms - The opportunities and challenges for genetic therapies for brain health - Exploring effective delivery of genetic payloads - Commercial viability and insurance considerations Listen here: https://lnkd.in/gWdJT3qR
Investor in frontier mental and brain health tech. Cofounder at PsyMed Ventures and Business Trip.
We've been thinking for a while about the place of genetic therapies in brain and mental health. Rather than just managing symptoms, these therapies address underlying dysfunctions. Saying they go to the source is too simplistic. But they might go to some of the sources. So, we invited one of my favorite VCs, Dana Watt, PhD, to discuss the science, business models, challenges, and the road ahead. Listen here: https://lnkd.in/gFVj2gni
PsyMed Ventures reposted this
We (PsyMed Ventures) are pleased to announce the release of our Environmental Toxins report, a comprehensive resource aimed at advancing knowledge and inspiring action among founders, researchers, and investors. https://buff.ly/4fpHZFE This report provides: 1️⃣ An overview of the health impacts associated with environmental toxins 2️⃣ A structured framework for identifying viable solutions 3️⃣ Insight into companies actively working on remediation 4️⃣ An analysis of emerging trends, risks, and opportunities in the field With policy shifts, advancing technology, and new scientific insights into how toxins interact with human health, the vast potential scope of this issue is coming into sharper focus. These same forces also signal that scalable solutions are on the horizon. Recent Additional Coverage: Twenty Years of Microplastic Pollution Research- (https://buff.ly/3BeaW8v) Science Environmental Neurotoxins and a Neurodegenerative Outbreak- (https://buff.ly/4hruqXO) American Journal of Medicine The Effects of Microplastics on Your Health & How to Reduce Them- (https://buff.ly/3Al9hxP) Huberman Lab They All Got Mysterious Brain Diseases. They’re Fighting to Learn Why - (https://buff.ly/3X85IDU) NY Times
We’re thrilled to welcome Brooks Leitner, MD-PhD, as a new partner at PsyMed Ventures. Brooks brings a rare blend of deep scientific expertise and clinical and entrepreneurial experience, leveling up our team as we pursue frontier opportunities in brain and mental health. Brooks has an MD-PhD from Yale University and has worked across three labs: the Perry Lab (Cellular & Molecular Physiology), the Exercise for Brain Health Lab at UMD, and the Metabolic Clinical Research Unit at The National Institutes of Health. Beyond academia, Brooks is also a founder and investor. He co-founded EpiTET Therapeutics, a biotech targeting an epigenetic regulator to address chronic diseases. On the investment side, he worked at Canaan Partners, Foresite Capital, and BrightEdge - American Cancer Society . Brooks hit the ground running—on day one, he said he had the excitement of “a dog in the pen before a race.”
Announcing the Future Neuro Founders Workshop co-hosted by PsyMed Ventures and KdT Ventures! This virtual workshop is for scientists (PhDs, MDs, postdocs, professors) who want to build a neuroscience startup. Sign up here: https://lu.ma/xox6edul Applications open today, October 21st and close November 10th. We have an exciting lineup of entrepreneurial scientists and VCs: ⭐ Matias Serebrinsky and Brooks Leitner of PsyMed Ventures ⭐ Patrick Malone, MD PhD of KdT Ventures ⭐ Amit Etkin of Alto Neuroscience ⭐ Alexandra Sakatos of Ancilia Biosciences ⭐ Brian Pepin of Rune Labs ⭐ Tyler Benster of Reflex Tech ⭐ Ian Peikon of Cajal Neuroscience ⭐ Jacob Robinson of Motif Neurotech Participants will gain insights on topics like transitioning from academia to entrepreneurship, how to build an early-stage team, and how to partner with investors. Nominate an entrepreneurial scientist by tagging them in the comments below!
PsyMed Ventures Director of Operations Caitlin Ner is speaking on the intersection of AI & Wellness at the Los Angeles TECH WEEK by a16z. Sign up here: https://lnkd.in/gBcqMd_w
We're hosting a panel for AI & Wellness this Thursday in Malibu for LA Tech Week with Shira Lazar, Amy Kelly and Caitlin Ner. You can sign up to join the event here: https://lnkd.in/gAikA63B See you there!!
PsyMed Ventures GP Matias Serebrinsky was featured on the latest Healthtech Unveiled newsletter. Read more here: https://lnkd.in/gA3U9qNt
Globally, an estimated 1 in 4 people will experience a mental illness at some point in their lives. Yet, only 2% of healthcare spending goes towards mental health services. In the U.S. alone, the economic cost of mental health disorders makes up an estimated $1 trillion annually in lost productivity. In my interview with Matias Serebrinsky, co-founder of PsyMed Ventures, we discussed how his team invests in groundbreaking neurotech, digital health, and precision psychiatry solutions that could transform mental health care for over 1 billion people. 🧑🔬💡 As Matias said, "The technologies that solve this mental health epidemic will enable a future where humans flourish." 🌟 🔗 Read more about how PsyMed Ventures is shaping the future of mental health in my latest article: "Harnessing Innovation: How PsyMed Ventures is Shaping the Future of Mental Health with New Technologies." #MentalHealth #Innovation #Neurotech #DigitalHealth #VentureCapital Matias Serebrinsky, Greg Kubin, Caitlin Ner, Dina Burkitbayeva, PsyMed Ventures
PsyMed Ventures reposted this
I started my career at a big bank. The hours and workload were intense. It's encouraging to see the conversation shift to include mental health. I'll be speaking at the Real Summit, one of the first conferences at the intersection of finance and mental health. 40 spots left, Oct 17-18 in NYC. Hope to see you there! https://lnkd.in/eYRJFM9G